TREAT Act
USA117th CongressHR-5663| House
| Updated: 10/22/2021
Diana Harshbarger
Republican Representative
Tennessee
Cosponsors (24)
Chip Roy (Republican)Barry Moore (Republican)Tim Burchett (Republican)Claudia Tenney (Republican)Mariannette Miller-Meeks (Republican)Scott Perry (Republican)Ronny Jackson (Republican)Pat Fallon (Republican)Roger Williams (Republican)Kat Cammack (Republican)Glenn Grothman (Republican)Brian J. Mast (Republican)W. Gregory Steube (Republican)John H. Rutherford (Republican)Charles J. "Chuck" Fleischmann (Republican)Austin Scott (Republican)Lauren Boebert (Republican)Byron Donalds (Republican)Julia Letlow (Republican)Scott DesJarlais (Republican)John W. Rose (Republican)Bill Posey (Republican)Louie Gohmert (Republican)Brian Babin (Republican)
Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Treatment Restoration for Emergency Antibody Therapeutics Act or the TREAT Act This bill prohibits the Department of Health and Human Services (HHS) from implementing any policy that restricts health care facilities from ordering and receiving COVID-19 monoclonal antibody therapies directly from manufacturers and distributors. In addition, the bill expressly nullifies a policy announced on September 13, 2021, under which HHS allocated supplies of these therapies through state or territorial governments.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Health
Cardiovascular and respiratory healthDrug therapyEmergency medical services and trauma careHealth care coverage and accessHealth facilities and institutionsHealth technology, devices, suppliesImmunology and vaccinationInfectious and parasitic diseasesState and local government operations
TREAT Act
USA117th CongressHR-5663| House
| Updated: 10/22/2021
Treatment Restoration for Emergency Antibody Therapeutics Act or the TREAT Act This bill prohibits the Department of Health and Human Services (HHS) from implementing any policy that restricts health care facilities from ordering and receiving COVID-19 monoclonal antibody therapies directly from manufacturers and distributors. In addition, the bill expressly nullifies a policy announced on September 13, 2021, under which HHS allocated supplies of these therapies through state or territorial governments.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Diana Harshbarger
Republican Representative
Tennessee
Cosponsors (24)
Chip Roy (Republican)Barry Moore (Republican)Tim Burchett (Republican)Claudia Tenney (Republican)Mariannette Miller-Meeks (Republican)Scott Perry (Republican)Ronny Jackson (Republican)Pat Fallon (Republican)Roger Williams (Republican)Kat Cammack (Republican)Glenn Grothman (Republican)Brian J. Mast (Republican)W. Gregory Steube (Republican)John H. Rutherford (Republican)Charles J. "Chuck" Fleischmann (Republican)Austin Scott (Republican)Lauren Boebert (Republican)Byron Donalds (Republican)Julia Letlow (Republican)Scott DesJarlais (Republican)John W. Rose (Republican)Bill Posey (Republican)Louie Gohmert (Republican)Brian Babin (Republican)
Health Subcommittee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Cardiovascular and respiratory healthDrug therapyEmergency medical services and trauma careHealth care coverage and accessHealth facilities and institutionsHealth technology, devices, suppliesImmunology and vaccinationInfectious and parasitic diseasesState and local government operations